Powered by: Motilal Oswal
2026-11-17 09:42:21 am | Source: Choice Institutional Equities Ltd
Buy Jeena Sikho Lifecare Ltd For Target Rs.440 by Choice Institutional Equities Ltd
Buy Jeena Sikho Lifecare Ltd For Target Rs.440 by Choice Institutional Equities Ltd

Execution Reset Delays Growth Visibility:

The past two quarters have exposed execution challenges, with investments in preventive healthcare and customer acquisition weighing on ARPOB, margin and profitability. The management has also reduced its FY27 guidance to ~INR 10 Bn revenue (from ~INR 11 Bn earlier) and 35–40% EBITDA margin (from 40%+ previously), following delays in key growth initiatives and slower-than-expected execution. Given that actual performance has consistently fallen short of the management's guidance, we build our estimates conservatively, forecasting FY27 revenue of INR 9.6 Bn and an EBITDA margin of 33%. We believe execution over the next few quarters will be critical to restoring confidence in the company's long-term growth trajectory. The board is considering buyback as well.

Revenue growth offset by higher operating expenses, impacting profitability

* Revenue grew by 23.9% YoY and 4.8% QoQ to INR 2,351 Mn (vs. CIE estimate of INR 2,230 Mn)

* EBITDA de-grew by 21.8% YoY and 21.8% QoQ to INR 720 Mn (vs. CIE estimate of INR 900 Mn); margin contracted by 1,786 bps YoY and 1,041 bps QoQ to 30.6% (vs. CIE estimate of 40.4%), miss was attributed to higher marketing expenses.

* PAT decreased by 37.7% YoY and 44.4% QoQ to INR 366 Mn (vs. CIE estimate of INR 570 Mn), with a PAT margin of 15.6%.

Growth opportunity intact, but execution needs to catch up:

While JSLL continues to strengthen its integrated Ayurveda ecosystem through hospital expansion, product additions and premium wellness offerings, the near-term investment case has become increasingly execution dependent following two consecutive quarters of weaker-than-expected profitability. The management has now recalibrated its strategy by refocusing on higher-value treatment services alongside preventive healthcare however, the moderation in FY27 guidance reinforces our cautious stance after recent performance fell short of earlier expectations. We remain constructive on the structural opportunity but adopt a more measured stance, factoring ~4,350 bed capacity by FY29E, well below the management's aspiration of 7,000–10,000 beds over the next 3–5 years, until execution demonstrates sustained improvement.

Multiple growth levers; Ayushman Bharat inclusion remains a key optionality:

While near-term execution remains the key monitorable, JSLL continues to develop newer growth avenues through newer revenue streams such as premium wellness, specialty care programmes and deeper insurance penetration. The management also anticipates government-funded Panchakarma volumes to gradually recover owing to improving payment timelines, while capping government business at ~15% of revenues. Separately, the potential inclusion of Ayurveda under the Ayushman Bharat scheme remains a meaningful optionality. While we do not factor any contribution from this into our base-case estimate, given the uncertainty around its implementation, any inclusion could materially improve occupancy, accelerate capacity utilisation and provide meaningful upside to our estimate.

View and valuation:

We expect JSLL to deliver Revenue/EBITDA/PAT CAGR of 20.4%/11.9%/13.3% over FY26–29E. We maintain our ‘BUY’ recommendation on JSLL and revise our target price to INR 440 on the basis of DCF valuation. This equates to an implied PE of 19x on avg of FY28–29 EPS and PEG of 1.3x which further supports our valuation.

 

For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer

SEBI Registration no.: INZ 000160131

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here